TH.TO实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (4 May 2024 @ 03:59):

Stats
今日成交量	9 815.00
平均成交量	25 111.00
市值	82.30M
EPS	$0 ( 2024-04-10 )
下一个收益日期	( $-0.0400 ) 2024-07-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.24
ATR14	$0.0100 (0.56%)

Theratechnologies Inc 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Theratechnologies Inc 财务报表

Annual	2023
营收:	$81.76M
毛利润:	$62.13M (75.99 %)
EPS:	$-0.910

FY	2023
营收:	$81.76M
毛利润:	$62.13M (75.99 %)
EPS:	$-0.910

FY	2022
营收:	$80.06M
毛利润:	$53.78M (67.17 %)
EPS:	$-0.500

FY	2021
营收:	$69.82M
毛利润:	$46.56M (66.69 %)
EPS:	$-0.340

Financial Reports:

No articles found.

Theratechnologies Inc

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.